Equities

10X Genomics Inc

0A88:LSE

10X Genomics Inc

  • Price (USD)18.50
  • Today's Change0.7272 / 4.09%
  • Shares traded3.51k
  • 1 Year change25.72%
  • Beta2.2414
Data delayed at least 20 minutes, as of Feb 06 2026 17:22 GMT.
More ▼

Financials data is unavailable for this security.

Cash flow Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2024202420232022
OPERATIONS
Net income(183)(255)(166)
Depreciation/depletion363625
Non-Cash items152187146
Cash taxes paid, supplemental5.644.933.93
Cash interest paid, supplemental00.440.84
Changes in working capital1.2517(39)
Total cash from operations6.66(15)(34)
INVESTING
Capital expenditures(13)(50)(132)
Other investing and cash flow items, total(19)183(219)
Total cash from investing(33)133(351)
FINANCING
Financing cash flow items0(5.81)(5.41)
Total cash dividends paid------
Issuance (retirement) of stock, net111921
Issuance (retirement) of debt, net----0
Total cash from financing111416
NET CHANGE IN CASH
Foreign exchange effects(0.16)(0.03)(0.04)
Net change in cash(15)132(369)
Net cash-begin balance/reserved for future use359227596
Net cash-end balance/reserved for future use344359227
SUPPLEMENTAL INCOME
Depreciation, supplemental363625
Cash interest paid, supplemental00.440.84
Cash taxes paid, supplemental5.644.933.93
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.